Abstract 164P
Background
Immune checkpoint inhibitors (ICI) were demonstrated to extend survival in patients with metastatic esophageal squamous cell carcinoma (ESCC). However, the role of ICI in locally advanced ESCC is not yet established. Herein, we conducted a retrospective study to evaluate the efficacy and safety of ICI plus neoadjuvant concurrent chemoradiotherapy (CCRT) for patients with locally advanced ESCC.
Methods
ESCC patients treated with neoadjuvant CCRT were retrospectively recruited into our study. Patients were classified into ICI-CCRT and CCRT according to regimens during CCRT. ICI-CCRT referred to ICI plus chemoradiotherapy while CCRT referred to chemoradiotherapy alone. Kaplan-Meier curves were estimated for recurrent-free survival (RFS) and overall survival (OS).
Results
A total of 150 patients were enrolled into our study, with 43 patients in ICI-CCRT and 107 patients in CCRT group. The median age was 58.5 years old of our patients and median follow-up period were 22 months. As for patients in ICI-CCRT, 33 patients received nivolumab plus CCRT and 10 patients received pembrolizumab plus CCRT. The median RFS was not reach (NR) versus 16.2 months in ICI-CCRT and CCRT group, respectively (p= 0.016). The median OS was not reach (NR) versus 20.0 months in ICI-CCRT and CCRT group, respectively (p= 0.002). The response rates were significantly higher in IC-CCRT, accounting for 74 % versus 65 % in ICI-CCRT arm and CCRT arm, respectively. Multivariate analysis showed ICI-CCRT was an independent predictor associated with survival. Grade 3/4 adverse events were comparable between each group.
Conclusions
Neoadjuvant ICI-CCRT is superior to CCRT for locally advanced ESCC patients with similar toxicity profiles. Further prospective studies are warranted to validate our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract